BUSINESS BRIEFING / PHARMACEUTICALS
Times Wire Reports
Amgen Inc.’s experimental drug denosumab worked as well as Novartis’ Zometa in preventing fractures in patients with advanced cancers whose disease had spread to their bones, the company said.
The 1,776-patient trial found that denosumab reduced the risk of fractures and other bone complications as effectively as Zometa, Amgen said.
Amgen, based in Thousand Oaks, is seeking approval in the U.S. and Europe to sell the drug to treat osteoporosis.
